공시 • Jun 24
Skye Bioscience Shares Nimacimab "Anatomy of Progress" Video Series and Highlights Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions
Skye Bioscience, Inc. announced the debut of its "Anatomy of Progress" nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association's (ADA) 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. In this four-part video series highlighted below, Skye discusses unmet needs in the obesity therapeutic space, advantages and benefits of its peripheral CB1-receptor-targeting antibody, which is designed to support healthy weight loss, and development progress of this novel CB1-inhibiting molecule. Skye's Chief Executive Officer, Punit Dhillon, commented on the important mechanistic advantages of nimacimab versus other CB1 inhibitors highlighted in this video update series: "Obesity isn't just a public health crisis, it's a biologically defended state, one that resists traditional treatments requiring smarter and safer interventions. "At Skye, we're developing nimacimab, a CB1 antibody that targets receptors in the periphery, while remaining greater than 99% excluded from the brain. Unlike the small molecule CB1 inhibitors currently in development, nimacimab's differentiating peripheral restriction has the potential to demonstrate the same weight loss and metabolic benefits previously seen in clinical trials by first-generation CB1 inhibitors, without the significant neuropsychiatric liabilities that continue to plague its small molecule counterparts. So nimacimab is not just another anti-obesity drug, it represents a new frontier in how it think about fat metabolism, safety and long-term care." Chapter 1: Nimacimab - A Differentiated CB1 Inhibitor for Obesity - A review of Skye's highly peripheral-restricted CB1 inhibitor and its potential advantages relative to the incretin class of anti-obesity drugs and small-molecule CB1 inhibitors, with recent preclinical data. Chapter 2: Nimacimab in the Clinic - Reviews Skye's current clinical activity and near-term Phase 2a clinical data readouts. Chapter 3: Market Opportunity for Nimacimab - Discusses input from obesity physicians that frames the distinct opportunity for a non-GLP1 obesity therapeutic with nimacimab's target product profile. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, an negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®?). Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, business, operating results, financial condition, and stock price could be materially negatively affected. The Company operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for management to predict all risks, nor can assess the impact of all factors on business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. R risks and uncertainties that may cause actual results to different materially include, among others, its capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Securities and Securities and Securities and Exchange.